Jade Biosciences Inc JBIO

$15.06 -0.43 (-2.78%)

Valuation

Market cap
1,065,511,000
Revenue TTM
$0
Net income TTM
$-127,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
508,600
Avg volume
974,720
Day's range
$15.00 – $15.87
Shares out
69,189,000
Stochastic %K
52%
Beta
1.81
Analysts
Strong Buy
Price target
$49.22

Price

Company profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc....

Show more

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 312 3013
Website
https://jadebiosciences.com
Address
Building 23, Suite 105 221 Crescent Street, Waltham, United States

Latest news

No headlines yet.